CoChat
Sign Up
Cited by 174Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and CancerCancer and biochemical research

The DOI matches its Crossref record; 133 of the 137 references it cites were found in a registry or an index.

Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment

Open access
Fan, Tengjiao, Sun, Guohui, Sun, Xiaodong, Zhao, Lijiao, Zhong, Rugang, Peng, Yongzhen·2019·Cancers
DOI 10.3390/cancers11030317PMC PMC6468516
Open this paper in CoChat — free accountOpen PDF

Abstract

Tumor formation and growth depend on various biological metabolism processes that are distinctly different with normal tissues. Abnormal energy metabolism is one of the typical characteristics of tumors. It has been proven that most tumor cells highly rely on aerobic glycolysis to obtain energy rather than mitochondrial oxidative phosphorylation (OXPHOS) even in the presence of oxygen, a phenomenon called “Warburg effect”. Thus, inhibition of aerobic glycolysis becomes an attractive strategy to specifically kill tumor cells, while normal cells remain unaffected. In recent years, a small molecule alkylating agent, 3-bromopyruvate (3-BrPA), being an effective glycolytic inhibitor, has shown great potential as a promising antitumor drug. Not only it targets glycolysis process, but also inhibits mitochondrial OXPHOS in tumor cells. Excellent antitumor effects of 3-BrPA were observed in cultured cells and tumor-bearing animal models. In this review, we described the energy metabolic pathways of tumor cells, mechanism of action and cellular targets of 3-BrPA, antitumor effects, and the underlying mechanism of 3-BrPA alone or in combination with other antitumor drugs (e.g., cisplatin, doxorubicin, daunorubicin, 5-fluorouracil, etc.) in vitro and in vivo. In addition, few human case studies of 3-BrPA were also involved. Finally, the novel chemotherapeutic strategies of 3-BrPA, including wafer, liposomal nanoparticle, aerosol, and conjugate formulations, were also discussed for future clinical application.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers11030317

Cites

133 of 133 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The energy metabolism of normal differentiated tissues and tumor or proliferating tissues. (A) In normal differentiated tissues, under aerobic condition, a molecule of glucose is first converted to two pyruvates via glycolysis in the cytosol, followed by undergoing TCA cycle to produce CO2 in the mitochondria. A total of 30 or 32 ATP molecules are generated during this process. Under anaerobic condition, glycolysis is preferential and less pyruvate is shifted to the oxygen-consuming mitochondria, only 2 ATP molecules are produced per molecule of glucose. (B) In tumor or proliferating tissues, mitochondrial function is still normal, but little mitochondrial oxidative phosphorylation (OXPHOS) continues in tumor cells. In order to satisfy the metabolic requirements of both energy and materials for rapidly proliferating cells, ~85% of the glucose is processed to lactate via glycolytic pyruvate even in the presence of oxygen and ~5% of the glucose is metabolized by OXPHOS. In addition, ~10% of the glucose is diverted into the upstream of pyruvate production for biosynthesis (e.g., pentose phosphate pathway, PPP).
Figure 1 The energy metabolism of normal differentiated tissues and tumor or proliferating tissues. (A) In normal differentiated tissues, under aerobic condition, a molecule of glucose is first converted to two pyruvates via glycolysis in the cytosol, followed by undergoing TCA cycle to produce CO2 in the mitochondria. A total of 30 or 32 ATP molecules are generated during this process. Under anaerobic condition, glycolysis is preferential and less pyruvate is shifted to the oxygen-consuming mitochondria, only 2 ATP molecules are produced per molecule of glucose. (B) In tumor or proliferating tissues, mitochondrial function is still normal, but little mitochondrial oxidative phosphorylation (OXPHOS) continues in tumor cells. In order to satisfy the metabolic requirements of both energy and materials for rapidly proliferating cells, ~85% of the glucose is processed to lactate via glycolytic pyruvate even in the presence of oxygen and ~5% of the glucose is metabolized by OXPHOS. In addition, ~10% of the glucose is diverted into the upstream of pyruvate production for biosynthesis (e.g., pentose phosphate pathway, PPP).CC BY · PubMed Central
Figure 2 Schematic representation of metabolism in tumor cells. Mutation-mediated continuous activation of PI3K/AKT signaling pathway upregulates the expression of glucose transporters (GLUTs) and substantially enhances the capture of glucose into the cytoplasm by HK, and activates PFK or upregulates PFK expression, leading to the high rate of glucose influx, which in turn facilitates the aerobic glycolysis. The glycolytic switch in tumor cells allows the direct or indirect flux of glycolytic intermediates to many biosynthetic pathways (e.g., PPP, amino acid synthesis, lipid synthesis, and nucleotide synthesis), which provides the biomacromolecules and other materials required for producing new daughter cells. In addition, the intermediates of glutaminolysis are also used for synthesizing biomass that rapidly growing tumor cells need.
Figure 2 Schematic representation of metabolism in tumor cells. Mutation-mediated continuous activation of PI3K/AKT signaling pathway upregulates the expression of glucose transporters (GLUTs) and substantially enhances the capture of glucose into the cytoplasm by HK, and activates PFK or upregulates PFK expression, leading to the high rate of glucose influx, which in turn facilitates the aerobic glycolysis. The glycolytic switch in tumor cells allows the direct or indirect flux of glycolytic intermediates to many biosynthetic pathways (e.g., PPP, amino acid synthesis, lipid synthesis, and nucleotide synthesis), which provides the biomacromolecules and other materials required for producing new daughter cells. In addition, the intermediates of glutaminolysis are also used for synthesizing biomass that rapidly growing tumor cells need.CC BY · PubMed Central
Figure 3 Schematic representation of tumor imaging by 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) technology.
Figure 3 Schematic representation of tumor imaging by 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) technology.CC BY · PubMed Central
Figure 4 Structure, decomposition, and mechanism of action of 3-BrPA. (A) Proposed mechanism of decomposition in solutions with different pH values. (B) Modification or inactivation of proteins, enzymes, or glutathione by 3-BrPA through the covalent binding of a pyruvic moiety to the thiol groups (especially the –SH group) of targets.
Figure 4 Structure, decomposition, and mechanism of action of 3-BrPA. (A) Proposed mechanism of decomposition in solutions with different pH values. (B) Modification or inactivation of proteins, enzymes, or glutathione by 3-BrPA through the covalent binding of a pyruvic moiety to the thiol groups (especially the –SH group) of targets.CC BY · PubMed Central
Figure 5 Underlying mechanism of 3-BrPA-mediated antitumor activity. 3-BrPA enters tumor cells via tumor-specific overexpression of monocarboxylate transporters (MCTs) (especially MCT1), followed by the inhibition of glycolysis (e.g., HK-II, GAPDH, and 3-PGK), mitochondrial OXPHOS (e.g., PDH, SDH, IDH, and αKD), PPP (e.g., G6PDH), glutaminolysis (e.g., IDH and αKD), the MG pathway (e.g., glyoxylase I and II), HDACs, and H+-vacuolar ATPase, downregulation of G6PDH and direct conjugation with GSH, leading to the decrease of intracellular ATP, an increase in oxidative stress (e.g., ROS), inhibition of anabolic process (e.g., PPP), carbonyl stress (e.g., MG), and destabilization of liposome. Consequentially, 3-BrPA selectively induces cell death by apoptosis or necrosis, while normal cell remains unaffected.
Figure 5 Underlying mechanism of 3-BrPA-mediated antitumor activity. 3-BrPA enters tumor cells via tumor-specific overexpression of monocarboxylate transporters (MCTs) (especially MCT1), followed by the inhibition of glycolysis (e.g., HK-II, GAPDH, and 3-PGK), mitochondrial OXPHOS (e.g., PDH, SDH, IDH, and αKD), PPP (e.g., G6PDH), glutaminolysis (e.g., IDH and αKD), the MG pathway (e.g., glyoxylase I and II), HDACs, and H+-vacuolar ATPase, downregulation of G6PDH and direct conjugation with GSH, leading to the decrease of intracellular ATP, an increase in oxidative stress (e.g., ROS), inhibition of anabolic process (e.g., PPP), carbonyl stress (e.g., MG), and destabilization of liposome. Consequentially, 3-BrPA selectively induces cell death by apoptosis or necrosis, while normal cell remains unaffected.CC BY · PubMed Central
Figure 6 Stable liposomal nanoparticle formulation for selectively delivering 3-BrPA to tumors.
Figure 6 Stable liposomal nanoparticle formulation for selectively delivering 3-BrPA to tumors.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 174

Related

See all

Metadata

Authors
Fan, T., Sun, G., Sun, X., Zhao, L., Zhong, R., & Peng, Y.
Affiliations
Beijing University of Technology (CN)
Corresponding author
Sun, Guohui
ORCID
Venue
Cancers
Publisher
MDPI AG
Published
2019-03-06
Volume
11
Issue
3
Pages
317
ISSN
2072-6694 (ISSN-L)
DOI
10.3390/cancers11030317
PMC
PMC6468516
OpenAlex
W2920277785
Cited by
171
References
137
Citations by year
2026: 12 · 2025: 17 · 2024: 17 · 2023: 32 · 2022: 29 · 2021: 32 · 2020: 22 · 2019: 10
FWCI
2.23
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Beijing Natural Science Foundation (7184192, 7162015)
  • Natural Science Foundation of China (21778011)
  • China Postdoctoral Science Foundation funded project (No. 2017M620567)
  • Beijing Postdoctoral Research Foundation (No. 2018-ZZ-022)
  • Chaoyang District Postdoctoral Research Foundation (No. 2018ZZ-01-25)
  • the Great Wall scholars program of Beijing Municipal Education Commission (No. CIT&TCD20180308)
  • Education Commission Science and Technology Project of Beijing Municipality (No. PXM2015_014204_500175)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
Keywords
3-bromopyruvate, aerobic glycolysis, Warburg effect, tumor energy metabolism, mitochondrial oxidative phosphorylation, glycolysis inhibitors, anticancer agents, combination chemotherapy, drug formulation, liposomal nanoparticles, aerosol drug delivery, alkylating agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review